tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alterity Therapeutics to Present Corporate Update at Biotech Showcase

Story Highlights
Alterity Therapeutics to Present Corporate Update at Biotech Showcase

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.

Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Biotech Showcase. This presentation highlights the company’s progress, particularly the positive data from its ATH434 trials for Multiple System Atrophy, potentially strengthening its position in the neurodegenerative disease treatment market.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials and is based in Melbourne, Australia, and San Francisco, USA.

YTD Price Performance: 40.0%

Average Trading Volume: 13,444,263

Technical Sentiment Signal: Sell

Current Market Cap: A$128.9M

Learn more about ATH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1